Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 500 participants.

Also called NCT06689839

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 500 participants (planned count) (from the registry)
Sponsor
EnCompass Technologies, Inc. (from the registry)
Registry
  • NCT NCT06689839
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Australia (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06689839. Randomized; single masking; primary purpose treatment. Start 2025-09-09 (actual); primary completion 2026-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR
Acronym
SHIELD
Condition
Aortic Stenosis Treated With TAVI
Condition
Aortic Diseases
Intervention (Device)
F2 Filter and Delivery System
Lead sponsor
EnCompass Technologies, Inc. (class: industry)
Collaborator
DP Clinical, Inc. (class: industry)
Collaborator
Avania Pty Ltd (class: not stated)

Record details

Record id
cardio:ct-nct06689839
Content hash
103c3e27149851947f8679befcbf5d0fb29ab838231464a422b3c71c0be823df